Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine

Pain

Volumn 126, Issue 1-3, 2006, Pages 165-174

  Koltzenburg, Martin ^a   Pokorny, Rolf ^b   Gasser, Urs E ^c   Richarz, Ute ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Swiss Pharma Contract Ltd   (Switzerland)

^c ClinResearch GmbH   (Switzerland)

^d Cilag AG   (Switzerland)

Author keywords

Acute pain models; Buprenorphine; Dose effectiveness; Double blind cross over study; Fentanyl; Healthy volunteers; Transdermal opioid delivery system

Indexed keywords

BUPRENORPHINE; FENTANYL; PARTIAL AGONIST; PLACEBO;

ANALGESIC ACTIVITY; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; ARTICLE; BACKACHE; CLINICAL TRIAL; COLD EXPOSURE; COLD PRESSOR TEST; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SENSITIVITY; DYSURIA; ELECTRIC INJURY; ELECTROSTIMULATION; EXPERIMENTAL MODEL; FATIGUE; FEMALE; HUMAN; INSOMNIA; MALE; MYALGIA; NAUSEA AND VOMITING; NORMAL HUMAN; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN IRRITATION; THERMAL EXPOSURE; URINE RETENTION;

ADMINISTRATION, CUTANEOUS; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; COLD; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTRIC STIMULATION; FEMALE; FENTANYL; HEAT; HUMANS; IMMERSION; MALE; PAIN; PAIN MEASUREMENT; SENSITIVITY AND SPECIFICITY;

EID: 33751307912     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.06.028     Document Type: Article

References (33)

1. Allan L., Hays H., Jensen N.-H., Le Polain de Waroux B., Bolt M., Donald R., et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322 (2001) 1154-1158
2. Allan L., Richard U., Simpson K., and Slappendal R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine 30 (2005) 2484-2490
3. Angst M.S., Drover D.R., Lotsch J., Ramaswamy B., Naidu S., Wada D.R., et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 94 (2001) 63-73
4. Arendt-Nielsen L., Nielsen J., Petersen-Felix S., Schnider T.W., and Zbinden A.M. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br J Anaesth 77 (1996) 625-631
5. ® and 2 × 25 mcg/h TDF in healthy volunteers. 1999. Inveresk Clinical Research Report No. 17406 (ICR013397).
6. Caldwell J.R., Rapoport R.J., Davis J.C., Offenberg H.L., Marker H.W., Roth S.H., et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 23 (2002) 278-291
7. Enggaard T.P., Klitgaard N.A., Gram L.F., Arendt-Nielsen L., and Sindrup S.H. Specific effect on venlafaxine on single and repetitive experimental painful stimuli in humans. Clin Pharmacol Ther 69,4 (2001) 245-251
8. Fruhstorfer H., Lindblom U., and Schmidt W.C. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 39 (1976) 1071-1075
9. Graven-Nielsen T., and Arendt-Nielsen L. Induction and assessment of muscle pain, referred pain, and muscular hyperalgesia. Curr Pain Headache Rep 7 (2003) 443-451
10. Hale M.E., Dvergsten C., and Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 6 (2005) 21-28
11. Jones S.F., McQuay H.J., Moore R.A., and Hand C.W. Morphine and ibuprofen compared using the cold pressor test. Pain 34 (1988) 117-122
12. Koppert W., Zeck S., Blunk J.A., Schmelz M., Likar R., and Sittl R. The effects of intradermal fentanyl and ketamine on capsaicin-induced secondary hyperalgesia and flare reaction. Anesth Analg 89 (1999) 1521-1527
13. Le Loet X., Pavelka K., and Richarz U. Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip, an open, multicentre study. BMC Musculoskelet Disord 6 (2005) 31
14. Leung A., Wallace M.S., Ridgeway B., and Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 91 (2001) 177-187
15. Luginbuhl M., Schnider T.W., Petersen-Felix S., Arendt-Nielsen L., and Zbinden A.M. Comparison of experimental pain tests to measure analgesic effects of alfentanil. Anaesthesia 95 (2001) 22-29
16. Milligan K., Lanteri-Minet M., Borchert K., et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2 (2001) 197-204
17. Muriel C., Failde I., Mico J.A., Neira M., and Sanchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther 27 (2005) 451-462
18. Naef M., Curatolo M., Petersen-Felix S., Arendt-Nielsen L., Zbinden A., and Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105 (2003) 79-88
19. Otis J.A.D., and Jones D. Clinical utility of a low dosage of TDF reservoir in the treatment of chronic, nonmalignant pain. Ann Rheum Dis 64 Suppl. III (2005) 528
20. Park K.M., Max M.B., Robinovitz E., Gracely R.H., and Bennett G.J. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain 63 (1995) 163-172
21. Park R., Wallace M.S., and Schulteis G. Relative sensitivity to alfentanil and reliability of current perception threshold vs von Frey tactile stimulation and thermal sensory testing. J Peripher Nerv Syst 6 (2001) 232-240
22. Pavelka K., Le Loet X., Bjorneboe O., Herrero-Beaumont G., and Richarz U. Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. Curr Med Res Opin 20 (2004) 1967-1977
23. Petersen K.L., Jones B., Segredo V., Dahl J.B., and Rowbotham M.C. Effect of remifentanil on pain and secondary hyperalgesia associated with the heat-capsaicin sensitization model in healthy volunteers. Anesthesiology 94 (2001) 15-20
24. Petersen K.L., Maloney A., Hoke F., Dahl J.B., and Rowbotham M.C. A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization. J Pain 4 (2003) 400-406
25. Petersen-Felix S., Arendt-Nielsen L., Bak P., Bjerring P., Breivik H., Svensson P., et al. Ondansetron does not inhibit the analgesic effect of alfentanil. Br J Anaesthesia 73 (1994) 326-330
26. Petersen-Felix S., Luginbuhl M., Schnider T.W., Curatolo M., Arendt-Nielsen L., and Zbinden A.M. Comparison of analgesic potency of xenon and nitrous oxide in humans evaluated by experimental pain. Br J Anaesthesia 81 (1998) 742-747
27. Price D.D., Milling L.S., Kirsch I., Duff A., Montgomery G.H., and Nicholls S.S. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 83 (1999) 147-156
28. Sethna N.F., Liu M.W., Gracely R., Bennett G.J., and Max M.B. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. Anesth Analg 86 (1998) 1250-1256
29. Sindrup S.H., Poulsen L., Brosen K., Arendt-Nielsen L., and Gram L.F. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?. Pain 53 (1993) 335-339
30. Sittl R., Griessinger N., and Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 25 (2003) 150-168
31. Sorge J., and Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 26 (2004) 1808-1820
32. Staahl C., and Drewes A.M. Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 95 (2004) 97-111
33. Van Strien G.A., and Korstanje M.J. Site variations in patch test responses on the back. Contact Dermatitis 31 (1994) 95-96